Synergistic Diarylalkane-Based Systems for Personalized Skin Treatment and Monitoring

Publication ID: 24-11857657_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Diarylalkane-Based Systems for Personalized Skin Treatment and Monitoring,” Published Technical Disclosure No. 24-11857657_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857657_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,657.

Summary of the Inventive Concept

The present inventive concept integrates diarylalkane-based compositions with distinct technologies such as AI, IoT, blockchain, and nanomaterials to create novel systems for personalized skin treatment, real-time monitoring, and secure authentication, thereby revolutionizing the skincare industry.

Background and Problem Solved

The original patent disclosed diarylalkane-based compositions for treating skin pigmentation due to inflammatory conditions. However, it lacked the capabilities for personalized treatment, real-time monitoring, and secure authentication, which are essential for effective skin treatment. The present inventive concept addresses these limitations by combining diarylalkane-based compositions with advanced technologies to provide a comprehensive solution for skin treatment and monitoring.

Detailed Description of the Inventive Concept

The inventive concept encompasses various systems and methods that integrate diarylalkane-based compositions with AI-driven skin analysis modules, IoT-enabled sensors, blockchain-based platforms, and nanomaterials. For instance, a system for personalized skin treatment comprises a diarylalkane-based composition and an AI-driven skin analysis module that determines optimal treatment regimens based on individual skin characteristics. Another embodiment includes a method for real-time monitoring of skin pigmentation using IoT-enabled sensors and a diarylalkane-based composition for treating skin pigmentation due to inflammatory conditions. Additionally, a blockchain-based platform can be used for secure tracking and authentication of diarylalkane-based compositions used in skin treatment, ensuring transparency and trust in the skincare industry.

Novelty and Inventive Step

The present inventive concept is novel and non-obvious in its integration of diarylalkane-based compositions with distinct technologies, providing a synergistic effect that enhances the efficacy and convenience of skin treatment and monitoring. The inventive concept's novelty lies in its ability to provide personalized treatment, real-time monitoring, and secure authentication, which are not achievable by the original patent alone.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include the use of other advanced technologies, such as machine learning algorithms, augmented reality, or biometrics, to further enhance the capabilities of the systems and methods. Variations of the inventive concept may also include the development of new diarylalkane-based compositions with improved efficacy or stability, or the integration of the inventive concept with existing skincare products or services.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the skincare industry, where personalized treatment and real-time monitoring are increasingly demanded. The market for skincare products and services is projected to grow significantly in the coming years, driven by the increasing awareness of skin health and the demand for effective and convenient solutions. The inventive concept's ability to provide a comprehensive solution for skin treatment and monitoring positions it for success in this growing market.

CPC Classifications

SectionClassGroup
A A61 A61K8/347
A A61 A61K8/31
A A61 A61K8/4973
A A61 A61K8/9789
A A61 A61K8/9794
A A61 A61K31/015
A A61 A61K31/05
A A61 A61K31/085
A A61 A61K31/09
A A61 A61K31/357
A A61 A61K31/40
A A61 A61K31/704
A A61 A61Q19/02
C C07 C07C39/15
C C07 C07C39/367
C C07 C07C41/26
C C07 C07C41/32
C C07 C07C43/23
C C07 C07C45/673
C C07 C07C49/835
C C07 C07C215/74
C C07 C07D321/12
A A61 A61K2800/782
Y Y02 Y02A50/30

Field of Art

Dermatological and cosmetic pharmaceutical technologies, specifically focused on enzyme inhibition, skin pigmentation treatment, and advanced drug delivery systems involving organic compounds and nanotechnology

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences, chemistry, or biomedical engineering, possessing expertise in enzyme inhibition, skin treatment technologies, and familiarity with emerging technologies like AI, IoT, and nanomaterials

Obviousness Rationale

A PHOSITA would recognize that integrating advanced technologies with existing diarylalkane-based skin treatments represents a predictable extension of the source patent's core innovations. The fundamental mechanism of treating skin pigmentation remains consistent, while the proposed technological integrations provide enhanced monitoring, personalization, and delivery mechanisms. These variations represent logical combinations of known techniques in pharmaceutical and digital health domains.

Obvious Combinations & Variations

Source Patent Element
Method for treating skin pigmentation using diarylalkane compounds
PTD Variation
AI-driven skin analysis module for determining personalized treatment regimens
Obviousness Reasoning
Personalized medicine is a well-established trend, and applying machine learning to optimize pharmaceutical treatments is a predictable technological progression for a PHOSITA
Source Patent Element
Compounds targeting skin pigmentation and inflammatory conditions
PTD Variation
IoT-enabled sensors for real-time skin monitoring and treatment tracking
Obviousness Reasoning
Integrating sensor technologies with pharmaceutical treatments is a known approach in digital health, representing an obvious enhancement to existing treatment methodologies
Source Patent Element
Diarylalkane compositions for skin treatment
PTD Variation
Nanomaterial-enhanced delivery systems for improved compound penetration
Obviousness Reasoning
Nanotechnology for drug delivery is a well-established technique, and applying nanomaterial enhancement to existing pharmaceutical compounds represents a standard optimization strategy
Source Patent Element
Skin pigmentation treatment method
PTD Variation
Blockchain platform for secure composition tracking and authentication
Obviousness Reasoning
Blockchain authentication for pharmaceutical products is an emerging but predictable technological solution for ensuring product integrity and traceability
35 U.S.C. § 103 Summary: Based on US Patent 11857657's teachings regarding diarylalkane-based skin treatments, the present publication demonstrates that integrating digital technologies, personalization algorithms, and advanced delivery mechanisms represents an obvious variation to a Person Having Ordinary Skill In The Art, thereby establishing prior art that would render similar claimed innovations non-patentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,657
TitleDiarylalkanes as potent inhibitors of binuclear enzymes
Assignee(s)Unigen, Inc.